Roche withdraws Tecentriq in bladder cancer amid FDA's sweeping review on accelerated approvals
The “industry-wide review of accelerated approvals” that’s been making waves in the checkpoint field has reached Roche.
With prodding from the FDA, the Swiss pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.